Differential response of angiotensin peptides in the urine of hypertensive animals

Regulatory Peptides

Volumn 80, Issue 1-2, 1999, Pages 57-66

  Yamada, Kazuo ^a   Iyer, Shridhar N ^a   Chappell, Mark C ^a   Brosnihan, K Bridget ^a   Fukuhara, Masayo ^a   Ferrario, Carlos M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin peptides; Hypertension; Lisinopril; Losartan

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN I; ANGIOTENSIN[1-7]; LISINOPRIL; LOSARTAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ELECTROLYTE EXCRETION; FLUID BALANCE; HEART RATE; HEMODYNAMICS; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY WEIGHT; DRINKING; ELECTROLYTES; HEMODYNAMIC PROCESSES; HYPERTENSION; LISINOPRIL; LOSARTAN; MALE; PEPTIDE FRAGMENTS; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 0032989024     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(99)00005-1     Document Type: Article

References (33)

1. 1 angiotensin receptor mRNA in spontaneously hypertensive rats. Am J Hypertens 1997;10:56S-62S.
2. Langheinrich M, Lee MA, Bohm M, Pinto YM, Ganten D, Paul M. The hypertensive Ren-2 transgenic rat TGR (mREN2)27 in hypertension research: characteristics and functional aspects. Am J Hypertens 1996;9:506-12.
3. Wilson KM, Magargal W, Berecek KH. Long-term captopril treatment. Angiotensin II receptors and responses. Hypertension 1988;11(Suppl. I):I148-52.
4. 1 receptor gene expression in transgenic (mRen-2) 27 rats. Br J Pharmacol 1997;121:134-40.
5. Chappell MC, Pirro NT, Sykes A, Ferrario CM. Metabolism of angiotensin-(1-7) by angiotensin converting enzyme. Hypertension 1998;31:362-7.
6. Gomez RA, Chevalier RL, Carey RM, Peach MJ. Molecular biology of the renal renin-angiotensin system. Kidney Int 1990;38(Suppl. 30):S18-23.
7. Chappell MC, Iyer SN, Diz DI, Ferrario CM. Antihypertensive effects of angiotensin-(1-7). Braz J Med Biol Res 1998;31:1205-12.
8. Ferrario CM, Martell N, Yunis C, et al. Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects. Am J Hypertens 1998;11:137-46.
9. Handa RK, Ferrario CM, Strandhoy JW. Renal actions of angiotensin-(1-7) in vivo and in vitro studies. Am J Physiol 1996;270:F141-7.
10. Ferrario CM, Chappell MC, Dean RH, Iyer SN. Novel angiotensin peptides regulate blood pressure, endothelial function and natriuresis. J Am Soc Nephrol 1998;9:1716-22.
11. Chappell MC, Diz DI, Yunis C, Ferrario CM. Differential actions of angiotensin(1-7) in the kidney. Kidney Int 1998;4:S3-6.
12. Iyer SN, Ferrario CM, Chappell MC. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 1998;31:356-61.
13. Iyer SN, Chappell MC, Averill DB, Diz DI, Ferrario CM. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998;31:699-705.
14. Yamada K, Iyer SN, Chappell MC, Ganten D, Ferrario CM. Converting enzyme determines the plasma clearance of angiotensin-(1-7). Hypertension 1998;98:496-502.
15. Benter IF, Diz DI, Ferrario CM. Cardiovascular actions of angiotensin-(1-7). Peptides 1993;14:679-84.
16. Kohara K, Tabuchi Y, Senanayake P, Brosnihan KB, Ferrario CM. Reassessment of plasma angiotensins measurement: effects of protease inhibitors and sample handling procedures. Peptides 1991;12:1135-41.
17. Moriguchi A, Brosnihan KB, Kumagai H, Ganten D, Ferrario CM. Mechanisms of hypertension in transgenic rats expressing the mouse Ren-2 gene. Am J Physiol 1994;266:R1273-8.
18. Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens 1996;14:799-805.
19. Azizi M, Guyene T-T, Chatellier G, Wargon M, Menard J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997;29:634-40.
20. Kohara K, Brosnihan KB, Ferrario CM. Angiotensin-(1-7) in the spontaneously hypertensive rat. Peptides 1993;14:883-91.
21. Campbell DJ, Duncan AM, Kladis A, Harrap SB. Angiotensin peptides in spontaneously hypertensive and normotensive donryu rats. Hypertension 1995;25:928-34.
22. Campbell DJ, Rong P, Kladis A, Rees B, Ganten D, Skinner SL. Angiotensin and bradykinin peptides in the TGR(mRen-2)27 rat. Hypertension 1995;25:1014-20.
23. Azizi M, Chatellier G, Guyene TT, Geoffroy DM, Menard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995;92:825-34.
24. Wagner J, Klotz S, Haufe CC, et al. Progression of renal failure after subtotal nephrectomy in transgenic rats carrying an additional renin gene (TGR(mREN)27). J Hypertens 1997;15:441-50.
25. Stasch J-P, Dietrich CH, Ganten D, Wegner M. Renal and antihypertensive effects of neutral endopeptidase inhibition in transgenic rats with an extra renin gene. Am J Hypertens 1996;9:795-802.
26. Wegner M, Hirth-Dietrich C, Knorr A, Dressel J, Ganten D, Stasch JP. Cardiorenal consequences of dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibition in transgenic rats with an extra renin gene. Hypertens Res 1996;19:151-9.
27. 1 receptor. Am J Hypertens 1998;11:5170-8.
28. Zou L-X, Hymel A, Imig JD, Navar G. Renal accumulation of circulating angiotensin II in angiotensin II-infused rats. Hypertension 1996;27:658-62.
29. Navar LG, Hymel LL, Braam B, Mitchell K. Comparison of intraluminal concentrations and kidney contents of angiotensin I and angiotensin II in anesthetized rats (Abstract). J Hypertens 1994;12:S157.
30. Chappell MC, Diz DI, Ferrario CM. Urinary angiotensin-(1-7): influence of converting enzyme and neprilysin inhibition. Hypertension 1995;26:542-.
31. Deddish PA, Marcic B, Jackman HL, Wang H-Z, Skidgel RA, Erdos EG. N-domain specific substrate and C-domain inhibitors of angiotensin converting enzyme. Hypertension 1998;31:912-7.
32. Garvin JL, Beierwaltes WH. Response of proximal tubules to angiotensin II changes during maturation. Hypertension 1998;31:415-20.
33. Navar LG, Zou L, VonThun AM, Wang CT, Imig JD, Mitchell KD. Unraveling the mystery of Goldblatt hypertension. News Physiol Sci 1998;13:170-6.